Literature DB >> 12860008

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

Apostolia Tsimberidou1, Jorge Cortes, Deborah Thomas, Guillermo Garcia-Manero, Srdan Verstovsek, Stephan Faderl, Maher Albitar, Hagop Kantarjian, Elihu Estey, Francis J Giles.   

Abstract

Clinical resistance to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia (AML) is associated with blast multidrug resistance (MDR) phenotype. A Phase II study of Mylotarg, fludarabine, ara-C and the MDR-modifier, cyclosporine (CSA) (MFAC) was conducted in 32 patients with primary resistant (11, 34%) or relapsed (21, 66%) AML. Nine (28%) patients obtained complete remission (CR), two (6%) CR with incomplete platelet recovery. Overall median survival was 5.3 months, 12-month survival rate 19%. Fourteen patients (44%) developed grade 3/4 hyperbilirubinemia; six (18%) grade 3/4 hepatic transaminitis; three (9%) hepatic veno-occlusive disease (VOD). CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12860008     DOI： 10.1016/s0145-2126(03)00022-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  6 in total

1.  Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

Authors:  Elias Jabbour; Guillermo Garcia-Manero; Jorge Cortes; Farhad Ravandi; William Plunkett; Varsha Gandhi; Stefan Faderl; Susan O'Brien; Gautam Borthakur; Tapan Kadia; Jan Burger; Marina Konopleva; Mark Brandt; Xuelin Huang; Hagop Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-04-24

Review 2.  What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?

Authors:  István Molnár; Bayard L Powell
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 3.952

Review 3.  Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia.

Authors:  Caroline Fenton; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Authors:  Akihiro Takeshita
Journal:  Int J Hematol       Date:  2013-05-26       Impact factor: 2.490

Review 5.  Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.

Authors:  Helen Ma; Ahmed Sawas
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 6.  Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.

Authors:  Hien K Duong; Mikkael A Sekeres
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.